Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25538247 | 0.82 | PARP1 (0.45) | PARP1HDAC1GPR119HSD11B1MAPK8 | |
| SCHEMBL30760013 | 0.81 | PARP1 (0.43) | PARP1HDAC1GPR119HSD11B1MAPK8 | |
| SCHEMBL27003346 | 0.81 | PARP1 (0.43) | PARP1HDAC1GPR119HSD11B1MAPK8 | |
| SCHEMBL4094782 | 0.81 | PARP1 (0.54) | PARP1HDAC1GPR119HSD11B1MAPK8 | |
| SCHEMBL4100723 | 0.81 | PARP1 (0.54) | PARP1HDAC1GPR119HSD11B1MAPK8 | |
| SCHEMBL25539655 | 0.81 | GPR119 (0.41) | GPR119USP30 | |
| SCHEMBL25678424 | 0.80 | PARP1 (0.42) | PARP1HDAC1GPR119HSD11B1MAPK8 | |
| SCHEMBL29860096 | 0.80 | PARP1 (0.42) | PARP1HDAC1GPR119HSD11B1MAPK8 | |
| SCHEMBL30249947 | 0.80 | JAK1 (0.47) | HDAC1GPR119HSD11B1 | |
| SCHEMBL25537184 | 0.80 | JAK1 (0.47) | HDAC1GPR119HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | BIOMEA FUSION, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023039240-A1 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | KRAS, NRAS, TP53 | PARP1 164/4885HDAC1 1766/4885GPR119 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.